Company Profile For Caraco Pharmaceutical Laboratories, Ltd.

Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers, throughout the United States and Puerto Rico. During the fiscal year ended March 31, 2009 (fiscal 2009), Caraco received United States Food and Drug Administration (FDA) approval for eight abbreviated new drug applications (ANDAs) relating to three products. It had filed 10 ANDAs relating to nine products with the FDA during fiscal 2009. This brings Caraco’s total number of ANDAs pending approval by the FDA to 29 (including four tentative approvals) relating to 25 products as of March 31, 2009.

BRIEF: For the six months ended 30 September 2009, Caraco Pharmaceutical Laboratories Ltd.'s revenues decreased 45% to $126.4M. Net loss totaled $2.8M vs. an income of $17.9M. Revenues reflect a decrease in sale of distributed products due to price erosion for the products sold and lower sales of caraco-owned products due to adverse affect by the actions of FDA. Net loss reflects the presence of interest expense.